PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris:BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced a 2008 turnover of €8.2 million, strongly increased from €3.5 million in 2007.
